Erlotinib

CAS No.:183321-74-6

TBW04189
ERLOTINIB;ERLOTINIB HCL;ERLOTINIB HCL SALT;4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline;n-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine;Erlotinib Hydrochloirde;4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-;Tarceva;ERLOTININ;Erlotinib &its intermediates (Developing);Erlortinib;Erlotinib (OSI-774,CP-358,774, Ro 50-8231);Erlotinib Base;Erlotinib Free Base;N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;(±)-Cloprostenol sodium;Erlotinib,OS-774;its intermediates;nchembio866-comp3;NSC718781;OSI 744;OSI-744;R1415;R-1415;UNII-J4T82NDH7E;J4T82NDH7E;[6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE;CP358774;N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine;AK142763;DSSTox_RID_81628;DSSTox_CID_26454;DSSTox_GSID_46454;Er;[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl);Erlotinib;ERLOTINIB [MI];SCHEMBL8413;L01XE03;AAKJLRGGTJKAMG-UHFFFAOYSA-N;Tox21_112202_1;1429636-49-6;Ro-508231;ERLOTINIB [WHO-DD];FT-0651539;NSC-800097;CHEBI:114785;HMS2089F05;CP-35877401;HMS3244M20;SR-05000001460;cid_176870;n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine monohydrochloride;SR-05000001460-2;NCGC00164574-14;ERLOTINIB [VANDF];SR-05000001460-1;SB16916;ERLOTINIB [EMA EPAR];RG-1415;(6,7-bis(2-methoxy-ethoxy)quinazoline-4-yl)-(3-ethynylphenyl)amine;SR-05000001460-6;MFCD02089651;EN300-708808;AB01273955-01;Erlotinib [INN:BAN];Erotinib;Kinome_3317;DB00530;DTXCID6026454;AB01273955-03;Erlotinib free base;NSC 718781;GTPL4920;NSC800097;[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine;OSI-774;NCGC00164574-06;AKOS000282911;SY028059;183321-74-6 (free base);HY-50896;Q418369;BRD-K70401845-003-04-7;K00241;HMS3244M19;HMS3244N19;Z2588038919;NCGC00164574-03;HMS3295A19;HSDB 8082;NCGC00164574-25;CAS-183321-74-6;Erlotinib(Tarceva);AB01273955-02;CHEMBL553;Tox21_112202;N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;Erlotinib, Free Base;CP-358,774;BCB03_000783;BE164419;erlotinibum;AC-399;SR-05000001460-3;HMS3745M05;4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline;NCGC00164574-01;(6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl)-(3-ethynyl-phenyl)-amine;BDBM5446;HMS3713C22;183321-74-6;R 1415;AS-35132;AM20090621;CS-0620;NCGC00164574-05;s7786;NS00006169;DTXSID8046454;CCG-220420;CP-358774
inquiry
C22H23N3O4
393.44

Product introduction

Category: Drug Impurities and Intermediates
Appearance: powder
Purity: 95~98%(HPLC)
Storage conditions: -20°C under seal save, placed in ventilated, dry environment
Application: All our products are for research and lab only. Injecting, eating and other ways are forbidden.
Package: 5mg,10mg ,20mg ,50mg ,100mg,1g, 100g or customized
SMILES: O(C([H])([H])C([H])([H])OC([H])([H])[H])C1C([H])=C2C(=NC([H])=NC2=C([H])C=1OC([H])([H])C([H])([H])OC([H])([H])[H])N([H])C1=C([H])C([H])=C([H])C(C#C[H])=C1[H]